Cilostazol Inhibits Vascular Smooth Muscle Cell Growth by Downregulation of the Transcription Factor E2F

Author:

Kim Mi-Jung1,Park Keun-Gyu1,Lee Kyeong-Min1,Kim Hye-Soon1,Kim So-Yeon1,Kim Chun-Soo1,Lee Sang-Lak1,Chang Young-Chae1,Park Joong-Yeol1,Lee Ki-Up1,Lee In-Kyu1

Affiliation:

1. From the Departments of Internal Medicine (M.-J.K., K.-G.P., K.-M.L., H.-S.K., I.-K.L.) and Institute for Medical Science, Physiology (S.-Y.K.), and Pediatrics (C.-S.K., S.-L.L.), Keimyung University School of Medicine, Daegu; Department of Pathology (Y.-C.C.), Catholic University of Daegu, School of Medicine, Daegu; and the Department of Internal Medicine (J.-Y.P., K.-I.U.), University of Ulsan College of Medicine, Seoul, Korea.

Abstract

Neointimal formation, the leading cause of restenosis, is caused by proliferation of vascular smooth muscle cells (VSMCs). Patients with diabetes mellitus have higher restenosis rates after coronary angioplasty than nondiabetic patients. Cilostazol, a selective type 3 phosphodiesterase inhibitor, is currently used to treat patients with diabetic vascular complications. Cilostazol is a potent antiplatelet agent that inhibits VSMC proliferation. In the present study, we examine whether the antiproliferative effect of cilostazol on VSMCs is mediated by inhibition of an important cell cycle transcription factor, E2F. Cilostazol inhibited the proliferation of human VSMCs in response to high glucose in vitro and virtually abolished neointimal formation in rats subjected to carotid artery injury in vivo. Moreover, the compound suppressed high-glucose–induced E2F–DNA binding activity, and the expression of E2F1, E2F2, cyclin A, and PCNA proteins. These data suggest that the beneficial effects of cilostazol on high-glucose–stimulated proliferation of VSMCs are mediated by the downregulation of E2F activity and expression of its downstream target genes, including E2F1, E2F2, cyclin A, and PCNA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3